BRIEF published on 04/02/2026 at 19:05, 6 months 28 days ago Medincell: Update on capital and voting rights Share Capital Voting Rights Shares Euronext AMF
PRESS RELEASE published on 04/02/2026 at 19:00, 6 months 28 days ago Informations privilégiées / Autres communiqués Euronext MEDCL divulgue les chiffres du capital social et des droits de vote conformément au règlement de l'AMF. Medincell développe des traitements biopharmaceutiques innovants à action prolongée Droits De Vote Euronext Capital Social Medincell MEDCL
BRIEF published on 02/20/2026 at 21:42, 8 months 10 days ago La suspension injectable d'olanzapine de Teva obtient l'approbation de la FDA Schizophrénie Olanzapine Teva Pharmaceuticals Acceptation Par La FDA Injectable À Action Prolongée
BRIEF published on 02/20/2026 at 21:42, 8 months 10 days ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 8 months 10 days ago Informations privilégiées / Autres communiqués La FDA américaine accepte le dossier de demande de mise sur le marché de l'Olanzapine LAI par Teva pour le traitement de la schizophrénie chez l'adulte. Une nouvelle option thérapeutique innovante pourrait bientôt être disponible FDA Schizophrénie Traitement Teva Olanzapine LAI
PRESS RELEASE published on 02/20/2026 at 21:37, 8 months 10 days ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
BRIEF published on 02/19/2026 at 10:33, 8 months 11 days ago Franchissement de seuil par Mirova chez MEDINCELL Euronext Paris Droits De Vote Cession D'actions Medincell Mirova
BRIEF published on 02/19/2026 at 10:33, 8 months 11 days ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
PRESS RELEASE published on 02/19/2026 at 10:28, 8 months 11 days ago Franchissement de seuil Déclaration de franchissement de seuil de la société MedinCell par Mirova. Baisse à 6,44% du capital et 4,89% des droits de vote Franchissement De Seuil AMF Baisse Medincell Mirova
BRIEF published on 12/09/2025 at 14:55, 10 months 21 days ago Medincell et Teva soumettent une demande d'autorisation de mise sur le marché auprès de la FDA pour un nouveau traitement injectable. Traitement De La Schizophrénie Medincell Soumission À La FDA Teva Pharmaceuticals Olanzapine LAI
Published on 10/30/2026 at 23:35, 2 hours 22 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 hours 27 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 5 hours 10 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 6 hours 57 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 10 hours 27 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 3 hours 8 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 7 hours 19 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 2 hours 57 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 2 hours 57 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
